Ayala Pharmaceuticals is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers which are identified as having an aberrant activation of the Notch pathway. Such activation has long been implicated in multiple solid tumor and blood-related cancers and has often been associated with more aggressive cancers.

Ayala’s technology offers an innovative therapeutic approach by addressing the underlying key drivers of tumor growth and initial clinical data shows that the company’s lead product may address the shortcomings of existing treatment options.